

Accepted Manuscript

Title: New and Upcoming treatments in Antiphospholipid Syndrome: a comprehensive review

Authors: Flavio Signorelli, Gustavo Guimarães Moreira Balbi, Vinicius Domingues, Roger Abramino Levy



PII: S1043-6618(17)31255-0
DOI: <https://doi.org/10.1016/j.phrs.2018.04.012>
Reference: YPHRS 3878

To appear in: *Pharmacological Research*

Received date: 1-10-2017
Revised date: 23-2-2018
Accepted date: 15-4-2018

Please cite this article as: Signorelli Flavio, Balbi Gustavo Guimarães Moreira, Domingues Vinicius, Levy Roger Abramino. New and Upcoming treatments in Antiphospholipid Syndrome: a comprehensive review. *Pharmacological Research* <https://doi.org/10.1016/j.phrs.2018.04.012>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

New and Upcoming treatments in Antiphospholipid Syndrome: a comprehensive review

Running header: New treatments in APS

Flavio Signorelli^{1,2}, Gustavo Guimarães Moreira Balbi³, Vinicius Domingues⁴, Roger Abramino Levy¹¹Department of Rheumatology, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil²Department of Internal Medicine, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil³Department of Rheumatology, Hospital Universitário, Universidade Federal de Juiz de Fora, MG, Brazil⁴Division of Rheumatology, New York University School of Medicine, New York, NY, USA.

Corresponding author: Flavio Signorelli, Rua Ribeiro Guimarães 80/1406 – Vila Isabel, Rio de Janeiro – RJ, 20541-038, Brazil.

E-mail: flasigno@hotmail.com

Graphical abstract




Figure 1. Target therapies and thrombotic APS pathogenesis

1 rituximab, belimumab; 2 peptide therapy; HCG; 3 TLR4 inhibitor; HCG; 4 vorasidol, DOACs, statins, vitamin D; 5 abocixibat, tirofiban, eptifibatid, HCG; 6 statins, vitamin D; 7 statins; 8 and 9 signaling inhibitors, statins; 10 sirolimus; 11 dapsone, ACE, peroxylamine, diltiazem, statins, vitamin D, CoQ10; 12 CoQ10; 13 HOQ, statins, CoQ10; 14 escitalopram, heparins, DOACs; 15 LDA, HCG; 16 AVK, heparins, DOACs.
 Legend: aPL - antiphospholipid; β2GPI - beta 2 glycoprotein I; DI and DV - Domain I and V; GPIa and GPIIb/IIIa - glycoprotein Ia and glycoprotein IIb/IIIa; ApoER2 - apolipoprotein E receptor 2; PAR - protease-activator receptor; sTfr-1 - soluble transmembrane tyrosine kinase-1; Ann2 - annexin 2; TLR4 - toll like receptor 4; p38MAPK - p38 mitogen activated protein; NFκB - nuclear factor kappa B; TF - tissue factor; TXB2 - thromboxane B2; IL - Interleukin; TNF - tumor necrosis factor; mTOR - mammalian target of rapamycin; HCG - hydroxychloroquine; CoQ10 - coenzyme Q10; ACE - angiotensin-converting enzyme; AVA - vitamin K antagonists; DOACs - direct oral anticoagulants; LDA - low dose aspirin.

Download English Version:

<https://daneshyari.com/en/article/8536281>

Download Persian Version:

<https://daneshyari.com/article/8536281>

[Daneshyari.com](https://daneshyari.com)